Serum Neurofilament Light Chain Levels in Small Fiber Neuropathy Patients with Skin Denervation and Ongoing Neuropathic Symptoms
Daniela Zohar1, Lamis Qassim1, Mailam Eltity1, Daria Keren1, Efrat Shavit1, Joab Chapman1, Amir Dori1
1Neurology Department, Sheba Medical Center
Objective:

To identify active axonal damage by measurement of serum neurofilament light chain (sNfL) levels in patients with small fiber neuropathy (SFN) and ongoing neuropathy symptoms.

Background:

SFN is associated with sensory symptoms and is evident by skin biopsy which show a reduction of the intraepidermal nerve fiber density (IENFD) indicating skin denervation. SFN patients may complain of prolonged/worsening symptoms, but it is not clear if this is associated with continuous axonal damage.  

Design/Methods:

Blood samples were collected from 95 consecutive patients that were referred for a skin biopsy due to suspected SFN. All patients had symptoms that were consistent with a clinical diagnosis of SFN. Patients were excluded if they had clinical or imaging evidence for a central nervous system disorder, electrodiagnostic abnormalities or absence of electrodiagnostic evaluation. Following these exclusions, 34 patients were included for analysis. Skin biopsy was performed 2-3 months from symptoms onset by 4 patients, 4-12 months by 7, and after more than 12 months by 23. Severe skin denervation was defined by an intraepidermal nerve fiber density (IENFD) below the 5th percentile per age, mild denervation when the IENFD was at the 5-20th percentiles, and above the 20th percentile was considered normal.

Results:
The majority of patients (29/34; 85%) showed normal sNfL levels and almost half of the patients showed skin denervation (15/34; 44%). Two patients with skin denervation (2/15; 13.3%) showed elevated sNfL, after 7 and more than 12 months from symptoms onset. The skin biopsy was normal in the other 3 patients with elevated sNfL, obtained 2, 8 and more than 12 months from symptoms onset. All patients with elevated sNfL had a history of chemotherapy treatment or immune-mediated disorders.
Conclusions:
In this cohort, a small portion of patients with SFN and skin denervation showed increased sNfL which indicated ongoing axonal damage. 
10.1212/WNL.0000000000202682